Chronic lymphocytic leukemia: A prognostic model comprising
only two biomarkers (IGHV mutational status and FISH
cytogenetics) separates patients with different outcome and
simplifies the CLL-IPI

J 2017

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI

DELGADO, Julio, Michael DOUBEK, Tycho BAUMANN, Jana KOTAŠKOVÁ, Stefano MOLICA et. al.

Basic information

Original name

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI

Authors

DELGADO, Julio (724 Spain), Michael DOUBEK (203 Czech Republic, belonging to the institution), Tycho BAUMANN (724 Spain), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Stefano MOLICA (380 Italy), Pablo MOZAS (724 Spain), Alfredo RIVAS-DELGADO (724 Spain), Fortunato MORABITO (380 Italy), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Emili MONTSERRAT (724 Spain)

Edition

American Journal of Hematology, Hoboken, John Wiley & Sons, 2017, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.303

RIV identification code

RIV/00216224:14740/17:00095652

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1002/ajh.24660

UT WoS

000399299300022

Keywords in English

INDEPENDENT PREDICTOR; MULTIVARIATE-ANALYSIS; GENOMIC ABERRATIONS; SURVIVAL ANALYSIS; CD38 EXPRESSION; DOUBLING TIME; 1ST TREATMENT; TRIAL; INDEX; GENE

Abstract

V originále

Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV+no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV+adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV15-30015A, research and development project

Name: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

NV15-31834A, research and development project

Name: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie

Citovat

DELGADO, Julio, Michael DOUBEK, Tycho BAUMANN, Jana KOTAŠKOVÁ, Stefano MOLICA, Pablo MOZAS, Alfredo RIVAS-DELGADO, Fortunato MORABITO, Šárka POSPÍŠILOVÁ and Emili MONTSERRAT. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. American Journal of Hematology. Hoboken: John Wiley & Sons, 2017, vol. 92, No 4, p. 375-380. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.24660.

@article{1387519,
   author = {Delgado, Julio and Doubek, Michael and Baumann, Tycho and Kotašková, Jana and Molica, Stefano and Mozas, Pablo and RivasandDelgado, Alfredo and Morabito, Fortunato and Pospíšilová, Šárka and Montserrat, Emili},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/ajh.24660},
   keywords = {INDEPENDENT PREDICTOR; MULTIVARIATE-ANALYSIS; GENOMIC ABERRATIONS; SURVIVAL ANALYSIS; CD38 EXPRESSION; DOUBLING TIME; 1ST TREATMENT; TRIAL; INDEX; GENE},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI},
   url = {http://onlinelibrary.wiley.com/doi/10.1002/ajh.24660/abstract;jsessionid=539A218FD2C364B21D3AA16CBF9E3418.f03t03},
   volume = {92},
   year = {2017}
}

TY  - JOUR
ID  - 1387519
AU  - Delgado, Julio - Doubek, Michael - Baumann, Tycho - Kotašková, Jana - Molica, Stefano - Mozas, Pablo - Rivas-Delgado, Alfredo - Morabito, Fortunato - Pospíšilová, Šárka - Montserrat, Emili
PY  - 2017
TI  - Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI
JF  - American Journal of Hematology
VL  - 92
IS  - 4
SP  - 375-380
EP  - 375-380
PB  - John Wiley & Sons
SN  - 03618609
KW  - INDEPENDENT PREDICTOR
KW  - MULTIVARIATE-ANALYSIS
KW  - GENOMIC ABERRATIONS
KW  - SURVIVAL ANALYSIS
KW  - CD38 EXPRESSION
KW  - DOUBLING TIME
KW  - 1ST TREATMENT
KW  - TRIAL
KW  - INDEX
KW  - GENE
UR  - http://onlinelibrary.wiley.com/doi/10.1002/ajh.24660/abstract;jsessionid=539A218FD2C364B21D3AA16CBF9E3418.f03t03
L2  - http://onlinelibrary.wiley.com/doi/10.1002/ajh.24660/abstract;jsessionid=539A218FD2C364B21D3AA16CBF9E3418.f03t03
N2  - Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV+no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV+adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.
ER  -

DELGADO, Julio, Michael DOUBEK, Tycho BAUMANN, Jana KOTAŠKOVÁ, Stefano MOLICA, Pablo MOZAS, Alfredo RIVAS-DELGADO, Fortunato MORABITO, Šárka POSPÍŠILOVÁ and Emili MONTSERRAT. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2017, vol.~92, No~4, p.~375-380. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.24660.

Detailed Information on Publication Record